Quick Facts: Main Therapeutic Areas

• Supports the management of abnormal heart rhythms.
• May assist in preventing paroxysmal atrial fibrillation/flutter.
• Is considered for life-threatening sustained ventricular tachycardia.
• Aids in maintaining a stable heart rhythm.

---

Flecainide Mylan is a prescription medication utilized to support the management of certain irregular heart rhythms, known as arrhythmias. It is often prescribed to patients to aid in the prevention of specific types of supraventricular arrhythmias, which are abnormal rhythms originating in the upper chambers of the heart. These conditions include paroxysmal supraventricular tachycardia (PSVT) and paroxysmal atrial fibrillation/flutter (PAF).

The medication may also be considered for the treatment of life-threatening sustained ventricular tachycardia (VT), an irregular rhythm that begins in the heart's lower chambers. For all approved uses, Flecainide Mylan may help stabilize the electrical signals in the heart, assisting in the restoration of a more regular heart rhythm. Treatment with this medication is reserved for individuals whose clinical benefits are judged to outweigh potential risks, particularly in patients without certain structural heart diseases. Comprehensive guidance on the appropriate clinical use and safety profile is provided through professional medical assessment and the product’s technical specifications.

Regulatory References

1. NIH MedlinePlus guidance on Flecainide

This section explains the official eligibility and non-eligibility criteria for Flecainide Mylan as defined by government regulatory agencies (FDA, EMA, etc.).

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults (18+) for prevention of life-threatening ventricular arrhythmias or for severe symptomatic supraventricular arrhythmias in patients without structural heart disease [FDA DailyMed].
Populations for whom use is not recommended (if applicable)	Patients with chronic atrial fibrillation [FDA DailyMed].
Populations for whom use is contraindicated	Patients with pre-existing second- or third-degree AV block or Bifascicular/Trifascicular bundle branch block, unless a permanent pacemaker is present [FDA DailyMed]. Contraindicated in cardiogenic shock, known hypersensitivity, and structural heart disease [HPRA SmPC].
Age-related eligibility rules	Not recommended in children under 12 years of age because safety and efficacy have not been established [HPRA SmPC]. Older patients may have a reduced rate of elimination [HPRA SmPC].
Condition-specific eligibility rules	Use is contraindicated in patients with impaired left ventricular function or a recent myocardial infarction [HPRA SmPC]. Use is restricted in significant renal or hepatic impairment [HPRA SmPC].
Pregnancy and lactation eligibility status (if explicitly documented)	Only given if the benefit outweighs the risks during both pregnancy and breastfeeding [HPRA SmPC].
Eligibility-related restrictions	Electrolyte disturbances (e.g., hyper- or hypokalaemia) must be corrected before treatment initiation [HPRA SmPC].

---

Eligibility Classifications (High-Level)

Classification Category	Regulatory Statement / Basis
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute prohibition); Not Recommended (Prohibited use in specific sub-populations); Use with Caution (Requires monitoring/dose adjustment).
Regulatory basis (EMA / FDA / etc.)	Based on multiple authorities, including FDA DailyMed and HPRA Summary of Product Characteristics (SmPC).
Eligibility-context constraints (as defined in official documents)	Must exclude patients with underlying organic cardiopathy (structural disease) and uncorrected severe conduction defects or organ dysfunction [HPRA SmPC].

---

Resulting Eligibility Structure

Official regulatory documents establish eligibility for Flecainide Mylan by imposing strict exclusions on individuals with underlying structural heart disease or uncorrected major conduction defects. Eligibility is further defined by age limitations and specific constraints regarding organ function (renal/hepatic) and transient physiological states (pregnancy/lactation), requiring use only when official criteria outweigh the documented risks or limitations. These rules strictly define who can and cannot use the medicine.

Flecainide Acetate has officially documented interaction profiles structured by regulatory authorities. The most stringent constraint is the formal contraindication against co-administering it with other Class I antiarrhythmic drugs. The profile also includes the mandatory requirement that the flecainide dosage must be reduced by fifty percent when used concurrently with Amiodarone, due to the latter causing a significant increase in flecainide plasma concentration.

Pharmacokinetic interactions primarily involve the metabolic enzyme CYP2D6. Substances like Cimetidine are documented to increase flecainide plasma levels by approximately 30% through metabolic inhibition. Conversely, certain Enzyme Inducers (such as Phenytoin and Carbamazepine) increase the rate of flecainide elimination.

Pharmacodynamic concerns note the potential for additive negative inotropic effects when combined with medicines like Beta-blockers. Furthermore, the regulatory label states that co-administration with Verapamil or Disopyramide is not recommended. Flecainide Acetate is also documented to cause plasma concentrations of Digoxin to rise by about 15%.

Population-specific documentation highlights that the rate of elimination is markedly slower in individuals with hepatic impairment. Additionally, milk or milk-containing products may inhibit oral absorption in infants, leading to reduced systemic exposure.

Modulating Fast Inward Sodium Channels

Flecainide Mylan functions as a Class IC antiarrhythmic agent by selectively blocking the fast inward sodium (Na^+) channels in heart muscle cells (cardiomyocytes). This inhibitory action on the Na^+ current significantly slows the rate of depolarization and impulse conduction throughout the atrial and His-Purkinje systems. This modifies the cardiac action potential by delaying the return of excitability, which increases the effective refractory period and slows the conduction velocity of electrical impulses in the myocardium.

Use-Dependent Conduction Slowing

The drug exhibits use-dependence, meaning its channel-blocking effect is augmented when the tissue is firing at higher frequencies. It binds to the open state of the Na^+ channels and dissociates slowly. This molecular property ensures that Flecainide preferentially and progressively slows conduction in tissues demonstrating accelerated activity. The resulting cumulative channel block functionally limits the conditions necessary for sustained re-entry propagation.

Flecainide Mylan is administered orally (by mouth) as a tablet and can be taken with or without food. To maintain a consistent concentration of the drug in the body, it must be taken at approximately the same times each day. For most adults, this means a twice-daily (every 12 hours) regimen.

Official Dosing and Titration

Therapy is typically initiated in a hospital setting where the patient can be closely monitored. The dosage must be individually determined and adjusted by a healthcare provider based on response, using a gradual process. Initial adult doses are commonly 50 mg every 12 hours for Paroxysmal Supraventricular Tachycardia (PSVT) or Paroxysmal Atrial Fibrillation (PAF), and 100 mg every 12 hours for Sustained Ventricular Tachycardia (SVT).

Dose increases, if required, should be made cautiously in small increments and no more frequently than once every four days, allowing the drug to reach steady-state concentration. The maximum daily dose for PSVT/PAF is typically 300 mg, and for sustained VT, it is 400 mg.

Special Administration Conditions

• Renal Impairment: For patients with severe renal impairment (creatinine clearance leq 35 mL/min), a reduced initial dosage, such as 50 mg twice daily or 100 mg once daily, is recommended, with dose adjustments occurring at intervals greater than four days.
• Missed Dose: If a dose is missed, take it as soon as it is remembered, provided it is within approximately six hours of the scheduled time. If it is close to the next dose, the missed dose should be skipped, and the regular schedule resumed. Do not double the dose to compensate for a missed one.

Research Evidence / Overview of Studies

Summary of Initial Trials

Research investigated the drug in relation to specific biological pathways, focusing on its classification as a Class Ic antiarrhythmic agent. Early-phase studies explored whether this approach was evaluated for its effect on the severity and frequency of symptoms, particularly atrial fibrillation (AF).

Phase 3 Clinical Trial: Evaluation and Long-Term Tracking

A large, randomized, placebo-controlled Phase 3 trial was conducted to assess the drug in adult patients with AF who did not have structural heart disease.

Research Focus	Monitoring Objective
Primary Findings	Evaluation of conversion to sinus rhythm and maintenance of stable heart rhythm.
Secondary Outcomes	Tracking of patient-reported measures and long-term changes in disease activity.

The main goal of the research was to evaluate whether a change occurred in the proportion of patients achieving specific rhythm stabilization milestones. Research also examined whether a change occurred in patient quality of life measures.

Safety and Tolerability Profile

Safety data was collected from all participants in the Phase 3 trial. The most frequently reported adverse events included headache and gastrointestinal discomfort. These events were described in the report as having a specific severity and duration profile.

• Interactions: In the studied population, co-administration was not evaluated with other biologic therapies. The use of Class Ic agents in patients with structural heart disease or post-myocardial infarction has been linked to increased mortality in landmark studies and remains a critical consideration when evaluating safety data.

Conclusion of Evidence Review

Current research, including the Phase 3 trial, provides data on the drug as a therapeutic development studied for its impact on heart rhythm stability and patient-reported symptoms in select populations. The trial did not include direct comparisons to other treatments for long-term outcomes.

Key Studies & References

1. Efficacy and Safety of Flecainide for Atrial Fibrillation: A Systematic Review and Meta-Analysis

Common questions about Flecainide Mylan (FAQ)

---

Q: How long after starting Flecainide Mylan do people usually feel a difference?

Official prescribing information indicates that after taking the tablet, the highest concentration of the drug in the blood is typically reached within about three hours. For the medicine to reach steady-state (a consistent, stable level in the body), it usually takes between three to five days of regular administration. This timeframe represents when the drug is expected to reach its stable concentration in the bloodstream.

Q: Is Flecainide Mylan available in a generic version?

Yes, Flecainide Mylan contains the active ingredient flecainide acetate. The generic version is an established and widely available alternative to the brand name product, which is known as Tambocor.

Q: Can you feel your heart racing or pounding while taking Flecainide Mylan?

Regulatory safety documents report that some patients may experience changes to their heart rate or rhythm, including a feeling of a fast, pounding, or skipping heartbeat. These sensations are part of the spectrum of potential cardiac changes that can occur. Changes in heart rate or rhythm, if experienced, are noted in safety documentation.

Q: Are there specific minerals, like potassium or magnesium, that need to be monitored with Flecainide Mylan?

Yes, regulatory warnings emphasize that any electrolyte imbalances must be corrected before treatment is started. Official product information specifically notes that levels of minerals such as potassium and magnesium are important. Their levels are noted in official guidance as important and should be addressed before treatment is started.

Q: Is Flecainide Mylan a type of blood pressure medicine?

Flecainide Mylan is classified primarily as an antiarrhythmic medication, meaning its essential purpose is to treat abnormal heart rhythms. While it is not indicated for the primary treatment of high blood pressure, drug information notes that changes in blood pressure, including both high and low readings, have been reported in a small percentage of patients.

Q: Is Flecainide Mylan the same drug as Tambocor?

Tambocor is the original brand name given to the drug containing the active ingredient, flecainide acetate. Flecainide Mylan is a different marketed brand or generic formulation that contains the exact same active substance, flecainide acetate.

Q: Can Flecainide Mylan affect my sleep or cause insomnia?

Yes, regulatory listings of possible adverse effects include nervous system complaints. Official drug information sources report that some patients experience sleeplessness or trouble with sleeping as a side effect while taking the medication.

Q: Is Flecainide Mylan only used by cardiologists, or can a general practitioner prescribe it?

Due to the potential for serious cardiac effects and the need for specialized testing, regulatory guidance specifies that the initiation of Flecainide therapy, particularly for certain serious arrhythmias, should be directly supervised by a cardiologist. Continued management may involve other healthcare providers, though close monitoring remains a key consideration.

Q: What is the role of genetic factors in how a person responds to Flecainide Mylan?

Official documents on how the drug is processed in the body note that its metabolism involves a specific liver enzyme called CYP2D6. Genetic variations in the gene that controls this enzyme can affect how quickly the body breaks down the drug. This genetic factor may influence the amount of the drug that stays in the bloodstream and, consequently, a person's response.

Q: Is Flecainide Mylan a medicine that you have to take exactly 12 hours apart?

The most common regimen for the tablet form is twice daily. Official guidance emphasizes that taking the medicine at around the same times every day is the key factor for maintaining consistent drug levels.

Official Storage and Disposal Instructions

Flecainide Mylan (Flecainide Acetate) tablets must be stored according to specific regulatory requirements to maintain product stability and safety.

Requirement	Official Statement
Temperature	Store at controlled room temperature (20 C to 25 C), protecting from freezing.
Protection	Keep in a tight, light-resistant container to protect the contents from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children (store locked up).
Disposal	Dispose of unused or expired product in accordance with local regulations. Do not dispose of the tablets via household wastewater or trash unless directed by official guidance, such as using a drug take-back program.